Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

SINERGIA

financed

Closed

advanced technologieS for drug dIscovery and precisioN mEdicine in vitRo modell...

advanced technologieS for drug dIscovery and precisioN mEdicine in vitRo modellinG human physiology and diseAse A key step in the drug development process is to predict information on safety, efficacy and mechanisms of action of a candidate molecule as early as possible in the pipeline (drug screening). To accomplish this aim, physiological... see more

29/02/2024

POLIMI

4M€

Project Budget: 4M€

Project leader

POLITECNICO DI MILANO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 11 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2024-02-29

MSCA-ITN-2019: Innovative Training Networks Objective:The Innovative Training Networks (ITN) aim to train a new generation of creative, entrepre...

I+D

Cerrada does 6 years

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

POLIMI

523.00K€ | Leader

IDIADA AUTOMOTIVE TECHNOLOGY

582.81K€ | participant

UNIVERSITEIT MAASTRICHT

531.24K€ | participant

BiomimX

261.50K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 54 months Date Start: 2019-08-09
End date: 2024-02-29

Project leader

POLITECNICO DI MILANO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 4M€

participation deadline Sin fecha límite de participación.

Project description A key step in the drug development process is to predict information on safety, efficacy and mechanisms of action of a candidate molecule as early as possible in the pipeline (drug screening). To accomplish this aim, physiological and pathological pre-clinical models that closely approximate the human body are required. The limited capabilities of most of the existing pre-clinical screening tools, unable to meet the physiological relevance required to screen out failing drug candidates, reflect in the current weak performances of drug discovery: high attrition rates indeed affect the process of taking drugs from lab to market. Despite emerging new technologies exist with potential for advancing the field of in vitro modelling, their successfully implementation in the drug discovery pipeline to make it more efficient is still challenging. This is also imputable to a lack of structured dialogue between academic technology providers, market-oriented and regulatory-aware CROs, Biotechs and Pharma companies, which finally affects the research, training and development pipeline. SINERGIA aims at integrating a training network where academic and non-academic actors contribute to unravel the potential of the synergistic and rational use of four key bioengineering technologies. In particular, SINERGIA features academic leading experts of i) organs-on-chip and microfabrication technologies; ii) bioreactor and tissue engineering; iii) 3D Bioprinting; iv) induced-pluripotent human stem cells. These techniques are deployed to CROs and Biotech Consortium members that will ensure rational development, exploitation, validation and compliancy with regulatory and industrial aspects. Ultimately, this concerted action will lead to advanced models of human physiology and diseases to be introduced in preclinical stages of an innovative and improved drug discovery pipeline.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers